These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17414516)

  • 1. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies for advanced prostate cancer.
    Konety BR; Getzenberg RH
    Semin Urol Oncol; 1997 Feb; 15(1):33-42. PubMed ID: 9050138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
    Gleave M; Miyake H; Chi K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():47-57. PubMed ID: 16273354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on castrate-resistant prostate cancer: 2010.
    Lassi K; Dawson NA
    Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
    Strother JM; Beer TM; Dreicer R
    Eur J Cancer; 2005 Apr; 41(6):954-64. PubMed ID: 15808961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
    Priolo C; Oh WK; Loda M
    IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New molecular targets in advanced prostate cancer.
    Dawson NA
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
    Motadi LR; Misso NL; Dlamini Z; Bhoola KD
    Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future innovations in treating advanced prostate cancer.
    Desai P; Jiménez JA; Kao C; Gardner TA
    Urol Clin North Am; 2006 May; 33(2):247-72, viii. PubMed ID: 16631463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.